Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2020 | Advances in recurrent endometrial cancer: adavosertib, a WEE1 inhibitor

Ursula Matulonis • 20 May 2020
ASCO 2020
Ovarian Cancer

Ursula Matulonis, MD, Dana-Farber Cancer Institute, Boston, MA evaluates advances in recurrent endometrial cancer treatment and highlights the development of adavosertib, a WEE1 inhibitor that shows over a 30% response rate and represents an additional therapy for patients with recurrent endometrial cancer. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Ursula Matulonis

6:40
KEYNOTE-100 update: pembrolizumab in patients with advanced recurrent ovarian cancer
Ursula Matulonis • 20 May 2020
3:47
Looking forward to ASCO: updates in ovarian cancer
Ursula Matulonis • 20 May 2020
3:10
Overview of ENGOT-OV16/NOVA of niraparib in ovarian cancer and why the results were not surprising
Ursula Matulonis • 7 Oct 2016
1:15
Introduction to KEYNOTE-100 trial of pembrolizumab in advanced recurrent ovarian cancer
Ursula Matulonis • 7 Oct 2016

Related Videos

0:39
Early diagnosis of ovarian cancer with Pap smears
Sergio Marchini • 8 Apr 2024
4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
1:11
Clonal hematopoiesis mutations in ovarian carcinomas
Rebecca Porter • 8 Apr 2024
0:49
MITO-16a/MANGO-OV2a: plasma TF as a prognostic marker in ovarian cancer
Sergio Marchini • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals